Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472
Indexed in
Immune Cell Functions in Pancreatic Cancer
ABSTRAKT
Pancreatic cancer kills nearly 29,000 people in the United States annuallyas many people as are diagnosed with the disease. Chemotherapeutic treatment is ineffective in halting progression of the disease. Yet, specific immunity to pancreatic tumor cells in subjects with pancreatic cancer has been demonstrated repeatedly during the last 24 years. Attempts to expand and enhance tumor-specific immunity with biotherapy, however, have not met with success. The question remains, "Why can't specific immunity regulate pancreatic cancer growth?" The idea that tumor cells have evolved protective mechanisms against immunity was raised years ago and has recently been revisited by a number of research laboratories. In pancreatic cancer, soluble factors produced by and for the protection of the tumor environment have been detected and are often distributed to the victim's circulatory system where they may effect a more generalized immunosuppression. Yet the nature of these soluble factors remains controversial, since some also serve as tumor antigens that are recognized by the same T cells that may become inactivated by them. Unless the problem of tumor-derived immunosuppressive products is addressed directly through basic and translational research studies, successful biotherapeutic treatment for pancreatic cancer may not be forthcoming.
-
Plate Janet, Clinical trials of vaccines for immunotherapy in pancreatic cancer, Expert Review of Vaccines, 10, 6, 2011. Crossref
-
Plate Janet M.D., Harris Jules E., Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer, Journal of Cellular Biochemistry, 94, 6, 2005. Crossref
-
Ishii Genichiro, Sangai Takafumi, Ito Takashi, Hasebe Takahiro, Endoh Yasushi, Sasaki Hiroki, Harigaya Kenichi, Ochiai Atsushi, In vivo andin vitro characterization of human fibroblasts recruited selectively into human cancer stroma, International Journal of Cancer, 117, 2, 2005. Crossref
-
Plate Janet M. D., Plate Aileen E., Shott Susan, Bograd Susan, Harris Jules E., Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas, Cancer Immunology, Immunotherapy, 54, 9, 2005. Crossref
-
Tseng Jennifer F., Willett Christopher G., Castillo Carlos Fernandez-del, Ryan David P., Clark Jeffrey W., Zhu Andrew X., Rattner David W., Winkelmann Jennifer L., Warshaw Andrew L., Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations, Pancreatology, 5, 1, 2005. Crossref
-
Cubillos-Ruiz Juan R., Engle Xavier, Scarlett Uciane K., Martinez Diana, Barber Amorette, Elgueta Raul, Wang, Li, Nesbeth Yolanda, Durant, Yvon, Gewirtz Andrew T., Sentman Charles L., Kedl Ross, Conejo-Garcia Jose R., Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity, Journal of Clinical Investigation, 2009. Crossref
-
Degrate Luca, Nobili Cinzia, Franciosi Claudio, Caprotti Roberto, Brivio Fernando, Romano Fabrizio, Leone Biagio Eugenio, Trezzi Rosangela, Uggeri Franco, Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients, Langenbeck's Archives of Surgery, 394, 1, 2009. Crossref
-
Morse Michael A, Hall Joseph Robert, Plate Janet MD, Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer, Expert Opinion on Biological Therapy, 9, 3, 2009. Crossref
-
Plate Janet M.D., Current Immunotherapeutic Strategies in Pancreatic Cancer, Surgical Oncology Clinics of North America, 16, 4, 2007. Crossref
-
Almhanna Khaldoun, Philip Philip A., Defining New Paradigms for the Treatment of Pancreatic Cancer, Current Treatment Options in Oncology, 12, 2, 2011. Crossref
-
Chu Carrie K., Sarmiento Juan M., Park Jaemin, Staley Charles A., Galloway John R., Adsay N. Volkan, Kooby David A., Differences in Presentation and Perioperative Outcome after Pancreaticoduodenectomy for Cancer and Benign Pancreatitis, The American Surgeon, 76, 6, 2010. Crossref
-
Storz Peter, Crawford Howard C., Carcinogenesis of Pancreatic Ductal Adenocarcinoma, Gastroenterology, 158, 8, 2020. Crossref
-
Markus M., Abendroth A., Noureddine R., Paul A., Breitenbuecher S., Virchow I., Schmid K. W., Markus P., Schumacher B., Wiesweg M., Wendling J., Mende B., Siveke J. T., Schuler M., Kasper S., Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy, Journal of Cancer Research and Clinical Oncology, 147, 2, 2021. Crossref
-
Baird Jason R., Fox Barbara A., Sanders Kiah L., Lizotte Patrick H., Cubillos-Ruiz Juan R., Scarlett Uciane K., Rutkowski Melanie R., Conejo-Garcia Jose R., Fiering Steven, Bzik David J., Avirulent Toxoplasma gondii Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment, Cancer Research, 73, 13, 2013. Crossref
-
Catanzaro Elena, Canistro Donatella, Pellicioni Valentina, Vivarelli Fabio, Fimognari Carmela, Anticancer potential of allicin: A review, Pharmacological Research, 177, 2022. Crossref
-
Liu Cunren, Yu Shaohua, Zinn Kurt, Wang Jianhua, Zhang Liming, Jia Yujiang, Kappes John C., Barnes Stephen, Kimberly Robert P., Grizzle William E., Zhang Huang-Ge, Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function, The Journal of Immunology, 176, 3, 2006. Crossref